{"id":"W2343845543","doi":"10.1007/s10549-016-3812-1","title":"Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University; Hôpital Charles-Le Moyne; Juravinski Cancer Centre; University Health Network; Hamilton Health Sciences; Princess Margaret Cancer Centre; Kingston General Hospital; Interior Health; Ottawa Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ipsen; AstraZeneca; Celgene; Genomic Health; Cancer Care Ontario; Pfizer; Cancer Research Institute","keywords":"Medicine; Internal medicine; PTEN; Cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Metastatic breast cancer; Triple-negative breast cancer; Estrogen receptor; Clinical endpoint; Adverse effect; Clinical trial; Disease; Biology; PI3K/AKT/mTOR pathway","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001399967,0.001758552,0.00213325,0.0005039568,0.0007760815,0.001064403,0.00128226,0.001351296,0.006843483],"category_scores_gemma":[0.001120509,0.0005381905,0.00161165,0.0007120605,0.001118092,0.000618916,0.0003940653,0.003884974,0.001059314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004832223,"about_ca_system_score_gemma":0.0088252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07882568,"about_ca_topic_score_gemma":0.3303452,"domain_scores_codex":[0.9996248,0.0001284557,0.000009616922,0.00004559938,0.00006536489,0.0001260158],"domain_scores_gemma":[0.9995499,0.00006294013,0.00005049598,0.00002494757,0.00003811171,0.000273568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7571575,0.01832616,0.007734514,0.001761301,0.003033408,0.0003808957,0.0003761737,0.003638873,0.01489607,0.001308337,0.04618212,0.1452047],"study_design_scores_gemma":[0.8645236,0.08591732,0.02560688,0.0001163939,0.001498125,0.000422486,0.0001900941,0.001686487,0.001573697,0.0005601927,0.01781142,0.00009324249],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9501621,0.01175958,0.0006150793,0.004174784,0.0005856257,0.003758637,0.01056914,0.0003646427,0.01801041],"genre_scores_gemma":[0.9444634,0.01060444,0.002779067,0.004980585,0.0002964329,0.00207087,0.01785612,0.0001381695,0.01681083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07882568,"threshold_uncertainty_score":0.1567338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1276228540309587,"score_gpt":0.4400756633405633,"score_spread":0.3124528093096046,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}